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Abstract
Background: Treatment guidelines suggest either a low-dose or high-dose approach when prescribing amikacin
for nontuberculous mycobacterial pulmonary disease (NTM PD), but data supporting the low-dose approach are
limited. The purpose of this study was to describe the safety and efficacy of the use of a low-dose of intravenous
amikacin in a cohort of patients with NTM PD.
Methods: We retrospectively reviewed all patients with NTM PD who received amikacin at our institution between
July 1, 2003 and February 28, 2017. Demographics, clinical, microbiological and radiological data, indication and
dose of amikacin, and adverse drug effects were recorded.
Results: A total of 107 patients received a regimen containing amikacin for a median (IQR) of 7 (4–11) months.
Seventy (65.4%) were female and the mean age (SD) was 58.3 (14.9) years. Amikacin was started at a median dose
of 9.9 (2.5) mg/kg/day. Ototoxicity was observed in 30/77 (39%) patients and it was related to female sex (OR 4.96,
95%CI 1.24–19.87), and total dose of amikacin per bodyweight (OR 1.62, 95%CI 1.08–2.43). Patients of East Asian
ethnicity were less likely to develop ototoxicity (0.24, 95%CI 0.06–0.95). Out of 96 patients who received amikacin
for more than 3 months, 65 (67.7%) experienced symptom improvement and 30/62 (49.2%) converted their sputum
to culture negative within a year.
Conclusions: Patients with NTM PD treated with low-dose intravenous amikacin frequently developed ototoxicity,
which was associated with female sex, and total dose of amikacin per bodyweight. Physicians should carefully
consider dose, treatment duration, and long term prognosis in balancing risks and benefits of intravenous amikacin
in NTM PD.
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Background
Nontuberculous mycobacteria (NTM) are ubiquitous mi-
croorganisms that may cause human infections, mainly af-
fecting the lungs. Nontuberculous mycobacteria
pulmonary disease (NTM PD) is often severe and requires
a long course of multidrug therapy [1]. Despite treatment,
prognosis is poor, and mortality remains high [1–4].
Use of injectable aminoglycosides has been associated
with higher rates of sputum conversion compared with
multidrug regimens not containing aminoglycosides in
Mycobacterium avium complex (MAC) [5] and Myco-
bacterium abscessus (M. abscessus) pulmonary disease
[6]. Guidelines from the American Thoracic Society /
Infectious Diseases Society of America (ATS/IDSA) rec-
ommend amikacin use as first line therapy against M.
abscessus pulmonary disease, advanced (especially fibro-
cavitary) or previously treated MAC pulmonary disease,
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and as second line therapy against some other NTM in-
fections [1]. The well described ototoxicity, vestibular
toxicity and renal toxicity due to amikacin limit the use
of this drug for prolonged periods of time. Moreover,
the correlation between clinical outcomes and amikacin
susceptibility testing break-points in patients with NTM
PD are not firmly established. Data suggest that a high
Minimum Inhibitory Concentration (MIC) for amikacin
is associated with worse clinical outcomes in MAC-PD
[7, 8], although formal recommendations have not yet
been developed for MAC-PD. There are no data regard-
ing the association between MIC for amikacin and clin-
ical outcomes in M. abscessus-PD, although M.
abscessus is considered susceptible to amikacin at a MIC
≤16 mcg/ml [9]. Furthermore, although treatment guide-
lines suggest either a low-dose or high-dose approach
when prescribing amikacin for NTM PD, data support-
ing the low-dose approach are scarce. Despite of all
these limitations, amikacin remains one of the most po-
tent drugs for the treatment of NTM PD, and therefore,
data on its risks and benefits are critical.
The objective of this study was to describe the safety
and efficacy of the use of low-dose intravenous amikacin
in a cohort of patients with NTM PD.
Methods
All patients with NTM-PD treated in the Toronto
Western Hospital NTM clinic between July 1, 2003 and
February 28, 2017 were retrospectively reviewed. Inclu-
sion criteria for the study were: a) diagnosis of NTM-PD
defined according to the ATS/IDSA criteria [1], and b)
treatment regimen that included intravenous amikacin
for any period of time. The study was approved by the
University Health Network Research Ethics Board. Base-
line demographic, clinical, microbiological and radio-
logical data were collected.
The predominant radiological pattern was classified as
nodular bronchiectatic, fibrocavitary, consolidation, ran-
dom nodules and unclassifiable based on computed
tomography (CT) [10]. Indication, dose and duration of
amikacin were also recorded.
Amikacin administration and toxicity
A Peripherally Inserted Central Catheter (PICC) was
inserted and the first dose of amikacin was administered
at the hospital and, if no adverse reactions, the following
doses were administered at an outpatient setting (infu-
sion clinic or patient residence), generally administered
during a 30-min infusion. Routine amikacin peak levels
were performed 30 to 45 min after amikacin infusion
every month, with the subsequent doses adjusted ac-
cordingly. Amikacin dosing followed the low-dose
approach suggested in the ATS/IDSA guidelines; the
starting dose was 8–10 mg/kg, typically given thrice
weekly (but ranging from 2 to 7 days per week), with the
dose adjusted to target a peak level of 20–25 mg/ml [1].
During our study period, the ATS/IDSA guidelines did
not significantly change with respect to amikacin dosing
recommendations. The 1997 guidelines did not provide
dosing recommendations for MAC, but for M. abscessus
they recommend either a low or higher dose approach,
either once or twice a day [11].
All patients who received amikacin for any duration
were reviewed for toxicities. Blood work including serum
creatinine was routinely performed every month while
on amikacin. Nephrotoxicity was defined as increase in
the absolute serum creatinine level of > 20 umol/L from
baseline or > 20% change in subsequent testing as in pre-
vious studies [12]. Audiograms during amikacin therapy
(advised to be done routinely) were recorded and com-
pared with audiograms performed before starting amika-
cin. Bilateral hearing was tested at 250, 500, 1000, 2000,
4000, and 8000 Hz. Patients whose hearing threshold
level were greater than 40 dB before starting amikacin
were considered as having disabling baseline hearing
impairment [13]. Ototoxicity was defined as a > 20 dB
neurosensory hearing loss from baseline in either ear at
any single frequency [14], seen on at least two consecu-
tive audiograms, unless only one audiogram was per-
formed after amikacin initiation. Persistent ototoxicity
was defined if neurosensory hearing loss was observed
after discontinuation of amikacin. Subjective symptoms
of ototoxicity were also recorded. Vestibular toxicity was
defined as having occurred if the patient reported com-
patible symptoms during a clinic visit, ie vertigo, dis-
equilibrium, or ataxia, +/− nausea/vomiting or physical
examination suggestive of vestibulotoxicity.
Sputum culture and drug susceptibility testing
Specimen culture was performed using the Bactec 460
TB system (Becton Dickinson Microbiology Systems,
USA) until May 2000 and, thereafter, with the Bactec
MGIT 960 system (Becton Dickinson Microbiology
Systems). Specimens were processed and analyzed as
described by Hanna et al. [15]. NTM cultures were
speciated using DNA probes (AccuProbe, Gen-Probe,
USA) for MAC and Mycobacterium gordonae, and by
high-performance liquid chromatography for other spe-
cies [16]. Drug Susceptibility Testing was performed
using the CLSI-recommended method of broth microdi-
lution, using commercially prepared microtiter dilution
plates (Thermo Fisher, Cleveland, OH) [9]. Concentra-
tions of amikacin tested ranged from ≤1 to 64 μg/ml.
Isolates with a MIC ≤16 were considered susceptible,
those with a MIC of 32 or 64 were considered inter-
mediate and those with a MIC > 64 were considered
resistant [8, 16]. Since amikacin Drug Susceptibility
Testing requires special request, it was not always
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requested in the early study period because of a lack of
data regarding clinical correlation.
Clinical and microbiological outcomes
Criteria for clinical outcomes and culture conversion
have been previously defined [17]. Characteristics of pa-
tients who converted their sputum were compared with
those of patients who continued to have positive cultures
after starting amikacin.
Statistical analysis
Descriptive statistics are presented as number (percent)
and median (Interquartile range, IQR) or mean (Stand-
ard deviation, SD) depending on variable normality. The
normal distribution of quantitative variables was tested
through the Shapiro–Wilk test. Categoric variables were
compared using chi-square tests or Fisher’s exact tests
and continuous variables were compared using t-tests or
Mann-Whitney tests. Demographics, dose and duration
of amikacin, repeated exposure to amikacin, baseline
weight, baseline serum creatinine and baseline disabling
hearing impairment were selected as potential risk fac-
tors of ototoxicity. Demographics, NTM species, CT
pattern, dose and duration of amikacin, and surgical
management were selected as potential prognostic vari-
ables for culture conversion. We developed two models
using a multivariate logistic regression analysis including
ototoxicity and culture conversion as dependent variables.
Variables with a p-value < 0.2 in the univariate analysis,
and variables considered a priori to be clinically important,
were included as independent variables. Multicollinearity
was explored using variance inflation factor (VIF). A
two-sided P value of 0.05 was used as the cutoff for statis-
tical significance. All analyses were performed using SPSS
statistical software (IBM SPSS version 23, Armonk, N.Y.).
Results
One hundred and seven patients were treated with a
regimen containing intravenous amikacin. Median dur-
ation of amikacin (IQR) was 7 (4–11) months. Table 1
shows baseline characteristics of patients treated with
amikacin. Forty-four (41.1%) patients had previously
been treated for NTM PD and one patient had received
amikacin previously at another institution. Amikacin
was started at a median (IQR) dose of 9.5 (8.3–10.4) mg/
kg/day, thrice weekly in 77 (72%) patients, 5 days weekly
in 20 (18.7%) patients, daily in 5 (4.7%) patients, twice
weekly in 4 (3.7%) patients, and every 48 h in 1 (0.9%)
patient. Amikacin was prescribed in combination with a
multidrug oral antibiotic regimen in all patients, and 33
(30.8%) patients underwent lung surgery (30 patients
underwent lung resection, 1 patient underwent lung
transplant, 1 patient underwent cardiopulmonary trans-
plant and 1 patient underwent a Clagett window).
Table 1 Baseline characteristics of patients treated with
amikacin
Baseline characteristics N = 107 (%)
Sex, Female 70 (65.4)
Age (Years), Mean (SD) 58.3 (14.9)
Race
Caucasian 72 (67.3)
South Asian 4 (3.7)
East Asian 28 (26.2)
African 3 (2.8)
Comorbidities
COPD/Emphysema 19 (17.7)
Previous TB 13 (12.1)
Cystic fibrosis 6 (5.6)
Asthma 5 (4.7)
Autoimmune disorders 5 (4.7)
Alpha 1 antitrypsin deficiency 2 (1.9)
Sarcoidosis 2 (1.9)
ABPA 2 (1.9)
Allogenic stem cell transplant 2 (1.9)
HIV infection 1 (0.9)
Species
MACa 69 (64.5)
M. abscessus 21 (19.6)
M. xenopi 11 (10.3)
MAC and M. xenopi 4 (3.7)
M. shimodei 1 (0.9)
M. fortuitum 1 (0.9)
AFB smear positive ever 100 (93.5)
Aspergillus isolation 39 (36.4)
CT pattern
Nodular bronchiectatic 55 (51.4)
Fibrocavitary 40 (37.4)
Random nodules 2 (1.9)
Consolidation 0 (0)
Unclassifiable 10 (9.3)
Cavity 66 (61.7)
Indication for treatment
First line 39 (36.4)
Second line 68 (63.6)
SD Standard deviation, COPD Chronic Obstructive Pulmonary Disease, TB
Tuberculosis, SLE Systemic Lupus Erythematous, ABPA Allergic
Bronchopulmonary Aspergillosis, HIV Human Immunodeficiency Virus, MAC
Mycobacterium avium complex, AFB Acid Fast Bacilli, CT
Computed Tomography
aFive patients had Clarithromycin resistant MAC; MAC isolates were not
identified to the species level prior to 2010, and so are reported as
MAC herein
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Twenty-four patients (22.4%) received a second course
of amikacin for a median (IQR) of 4 (3–10) months, in-
cluding 9 (37.5%) patients who restarted all antibiotics
due to an infection recurrence and 15 (62.5%) who never
stopped the oral antibiotics and were re-started on ami-
kacin due to worsening of their symptoms. Nine patients
(8.4%) received a third course of amikacin for a median
(IQR) of 26 (4.5–35) months. Median (IQR) total dose
of amikacin was 50.5 g (27.3–106.7).
The first course of amikacin was discontinued in 34
(31.8%) patients due to an adverse effect (17 (50%) oto-
toxicity, 6 (17.6%) fatigue, 4 (11.8%) renal insufficiency, 5
(14.7%) generalized skin rash, 1 (2.9%) paresthesias, and
1 (2.9%) restless extremities), 4 (3.7%) patients discontin-
ued treatment due to poor improvement of symptoms
and 4 (3.7%) discontinued amikacin for other reasons
(need to travel in 1 case, need to treat another infection
in 1 case, and poor adherence in 2 cases). Ten (9.3%) pa-
tients died while on amikacin. Causes of death were
NTM progression in 6 patients, postoperative complica-
tion after adjuvant lung resection in 2 patients, aspergil-
losis in 1 patient and cardiac arrest in 1 patient. Out of
24 patients who received a second course of amikacin,
10 (41.7%) stopped the amikacin due to an adverse effect
(5 ototoxicity, 2 skin rash, 2 PICC infection and 1 vestibu-
lar toxicity), 1 stopped amikacin due to poor clinical re-
sponse, and 2 stopped amikacin due to a need to treat
other medical conditions. Out of 9 patients who received
a third course of amikacin, 2 were still on amikacin at the
end of the study, 1 completed the treatment course, 4 de-
veloped an adverse effect (acute renal insufficiency in 1
patient, ototoxicity in 1 patient, skin rash in 1 patient and
fatigue in 1 patient), and 2 died due to NTM progression.
Adverse effects
Four (3.7%) patients developed vestibular toxicity after
starting amikacin. Blood work was available in 96
patients, and it showed elevated serum creatinine con-
centrations in 6 (6.2%) patients. Renal insufficiency was
reversible in 5 patients after stopping amikacin and in 1
after decreasing the dose of amikacin. Seven (6.5%)
patients experienced a PICC associated thrombosis, one
of them was diagnosed of a factor V Leyden deficiency
thereafter, and one patient developed a Staphylococcus
aureus bacteremia. Five patients developed a skin rash
that disappeared after stopping the amikacin. Six
patients experienced severe fatigue while on amikacin
that lead to discontinuation of treatment. Table 2
summarizes the adverse effects associated with amikacin.
Ototoxicity
Forty-three (40.2%) patients developed subjective oto-
toxicity while on amikacin; 32 reported tinnitus, 7
reported subjective hearing loss and 4 reported both
symptoms. Audiograms were available in 77 (72%)
patients. Five (6.5%) patients only had one follow up
audiogram. Overall, there was objective ototoxicity in 30
(39%) patients; 16 (53.3%) of these 30 patients reported
subjective ototoxicity. Out of 34 patients with subjective
ototoxicity who had an audiogram, 16 (47.1%) had evi-
dence of objective ototoxicity. Ototoxicity appeared a
median of 5.5 (3–11) months after the initiation of ami-
kacin. Although high frequency hearing loss (>2000 Hz)
was seen most often, 3 (10%) of the 30 patients showed
deficits in both high and low frequencies.
Patients developing ototoxicity were more likely to be
female (OR 4.96, 95%CI 1.24–19.87, p = 0.024), received
a higher total dose of amikacin per baseline bodyweight
(g/kg) (OR 1.62, 95%CI 1.08–2.43, p = 0.020) and were
less likely to be of East Asian ethnicity (OR 0.24, 95%CI
0.06–0.95, p = 0.042) than patients who did not develop
ototoxicity. This information is summarized in Table 3.
Amikacin MIC
Twenty-six patients (14 infected by MAC and 12 infected
by M. abscessus) had amikacin Drug Susceptibility Testing
before initiating this agent. Out of 14 MAC isolates tested,
11 (78.6%) showed susceptibility to amikacin, 2 (14.3%)
showed intermediate resistance and 1 (7.1%) was resistant
to amikacin. Eleven (91.7%) M abscessus isolates were
susceptible to amikacin, and 1 (8.3%) was resistant. Three
out of 4 patients whose isolates were either intermediate
or resistant to amikacin had not been previously exposed
to aminoglycosides. Thirteen patients had repeat Drug
Susceptibility Testing after receiving amikacin and one of
them developed amikacin resistance.
Microbiological and clinical outcomes
Sixty-five (67.7%) of the 96 patients who received a first
course of amikacin for ≥3 months experienced
Table 2 Adverse effects associated with amikacin
Adverse effects N (%)
Ototoxicity
Subjective symptoms 43/107 (40.2%)
Hearing impairment seen in audiograms 30/77 (39.0%)
Nephrotoxicity 6/96 (6.2%)
Vestibular toxicity 4/107 (3.7%)
PICC related complications
Venous thromboembolism 7/107 (6.5%)
Bloodstream infection 1/107 (0.9%)
Fatigue 6/107 (5.6%)
Skin rash 5/107 (4.7%)
Paresthesias 1/107 (0.9%)
Restless extremities 1/107 (0.9%)
PICC Peripherally Inserted Central Catheter
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improvement in their symptoms after starting amikacin
and 31 (45.6%) out of 68 patients who had a previous
positive sputum culture before starting amikacin and fol-
low up sputum after amikacin initiation converted their
sputum within a year following the initiation of amika-
cin. Twenty-six patients experienced persistent culture
conversion. None of the 15 patients who received a re-
current (second or third) course of amikacin for ≥3
months and who had a positive culture before starting
amikacin achieved sputum culture conversion.
Patients who achieved sputum culture conversion
underwent surgery more often than those who did not
achieve sputum culture conversion (61.3% vs 5.4%, p <
0.001). Excluding patients who underwent surgery, 12/
47 (25.5%) of patients achieved sputum culture conver-
sion. One of the 2 patients with a MIC for amikacin > 64
achieved sputum culture conversion. In the multivariate
logistic regression model, surgical intervention was the
only variable associated with sputum culture conversion
(OR 33.01, 95%CI 4.79–22.70, p < 0.001). Factors
associated with sputum culture conversion are shown in
Table 4.
Discussion
We observed that ototoxicity was common, and it was
associated with female sex, and total dose of amikacin
per bodyweight in patients with NTM PD. Vestibular
toxicity and nephrotoxicity were not frequently ob-
served. Most patients had symptomatic improvement
after starting amikacin, however, only half of them
achieved sputum culture conversion.
Amikacin has been shown to be an effective drug in
the management of NTM PD, especially in patients with
cavitary disease and in those whose isolate is macrolide
resistant MAC or M. abscessus [6, 18, 19]. However, the
potential adverse effects due to aminoglycosides limit
the use of these drugs. The most common adverse effects
due to aminoglycosides are ototoxicity, vestibular toxicity
and nephrotoxicity [20, 21]. Previous studies describing
patients with NTM pulmonary disease treated with
Table 3 Comparison of demographic and clinical characteristics in patients with and without audiographically demonstrated
ototoxicity
Ototoxicity
N = 30
No ototoxicity
N = 47
Univariate model Multivariate modela
OR (95%CI) P value OR (95%CI) P value
Sex, female 24 (80%) 29 (61.7%) 2.48 (0.85–7.24) 0.096 4.96 (1.24–19.87) 0.024
Age (years), median (IQR) 61 (43–65) 65 (51–72) 0.98 (0.95–1.01) 0.247 0.98 (0.94–1.02) 0.297
Race
Caucasian 22 (73.3%) 29 (61.7%) 1.71 (0.63–4.64) 0.295
South Asian 1 (3.3%) 1 (2.1%) 1.59 (0.09–26.36) 0.748
East Asian 6 (20%) 16 (34%) 0.48 (0.16–1.42) 0.188 0.24 (0.06–0.95) 0.042
African 1 (3.3%) 1 (2.1) 1.59 (0.09–26.36) 0.748
Weekly dose AK per bodyweight
(mg/kg/week), median (IQR)b
29 (23.7–41.3) 25.2 (21.8–29.4) 1.05 (1.00–1.10) 0.047 1.03 (0.98–1.09) 0.248
Months on AK, median (IQR) 11.5 (7–18.25) 7 (4–10) 1.04 (1.00–1.08) 0.052
Total dose AK per bodyweight (g/kg),
Median (IQR)c
1.81 (0.85–3.13) 0.74 (0.51–1.27) 1.59 (1.08–2.33) 0.018 1.62 (1.08–2.43) 0.020
Total dose AK (g), Median (IQR)d 77.3 (52.9–196.3) 41.7 (25.6–67.5) 1.01 (1.00–1.02) 0.011
Repeated exposure to amikacin 9 (30%) 10 (21.3%) 1.59 (0.56–1.52) 0.388
Baseline weight (kg), Median (IQR) 51.5 (41–66.5) 55 (48–64) 0.99 (0.96–1.03) 0.712
Initial serum creatinine (umol/L),
mean (SD)
66.0 (56.7–74.0) 63 (53–75) 1.01 (0.97–1.04) 0.656
Baseline disabling hearing impairment 8 (26.7%) 24 (51.1%) 0.35 (0.13–0.94) 0.037 0.54 (0.17–1.74) 0.305
Current treatment with macrolides 29 (96.7%) 45 (95.7%) 1.23 (0.11–14.87) 0.839
Nephrotoxicity 1 (3.6%) 4 (8.5%) 0.38 (0.04–3.58) 0.398
IQR Interquartile Range, AK Amikacin
aVariables with a p-value < 0.2 in the univariate analysis, and variables considered a priori to be clinically important, were included in the multivariate model,
wherein multicollinearity was explored using variance inflation factor (VIF). Months on amikacin and total dose amikacin per bodyweight both had VIFs> 10, and
so were eliminated
bOR represents risk associated with each increase of 1 mg/kg/week
cOR represents risk associated with each increase of 1 g/kg total dose
dOR represents risk associated with each increase of 1 g total dose
Total dose of amikacin and months on amikacin were excluded from the multivariate analysis due to collinearity
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regimens containing aminoglycosides have reported a
variable incidence of adverse effects, although doses and
duration of amikacin varied among studies [6, 12, 14].
In our study, we observed that 39% of patients experi-
enced ototoxicity after a median of 5.5 (3–11) months of
amikacin. Peloquin and colleagues observed a similar in-
cidence of ototoxicity (37%). Although the doses used in
our study are lower than the doses used in the Peloquin
study (median dose of 9.5 mg/kg thrice weekly vs. 15
mg/kg daily or 25 mg/kg thrice weekly, respectively), the
total duration of amikacin used in our study was longer
(median 33 vs. 15 weeks), so the total dose of amikacin
per kilogram bodyweight was similar (909mg/kg in our
study vs. 1012mg/kg in the daily dose group and 967
mg/kg in the thrice-weekly dosing group in the Peloquin
study). Lee et al. observed a 25% rate of ototoxicity in
patients infected by M. abscessus receiving a median
dose of amikacin of 19.3 mg/kg/day during 4 weeks [22].
Ellender et al. observed a 18% rate of ototoxicity in pa-
tients with NTM PD receiving a median dose of 22 mg/
kg/day for a median of 8.64 weeks [6, 12]. Although the
total dose of amikacin per bodyweight was not provided
from the studies by Ellender et al. and Lee et al., it can
be calculated that patients received approximately 462
mg/kg and 540 mg/kg cumulative doses respectively; the
lower total dose per bodyweight used in these studies
may explain the lower rates of ototoxicity observed,
compared with the Peloquin study and our study.
We observed that most patients with ototoxicity expe-
rienced hearing impairment in higher frequencies.
Aminoglycosides cause degeneration of hair cells in the
organ of Corti, predominantly in the basal turn which is
required to sense high-frequency sounds, so
high-frequency hearing loss is more common in patients
developing ototoxicity related with aminoglycosides [23].
Half of our patients with subjective symptoms of ototox-
icity had a normal audiogram. The absence of objective
hearing changes in patients reporting symptoms of oto-
toxicity have been previously reported [14] and it might
be due to different mechanisms of ototoxicity. Some of
the subjective symptoms could be related to an acute
and not permanent toxicity due to high dose aminogly-
cosides and may not be reflected in audiograms [24]. In
addition, we did not review changes in speech recogni-
tion thresholds, which may potentially vary from
changes in the pure-tone audiogram thresholds.
Table 4 Patient characteristics and their association with sputum culture conversion
Sputum culture
conversion
N = 31
No sputum
culture
conversion
N = 37
Univariate model Multivariate model
OR (95%CI) P value OR (95%CI) P value
Sex, female 23 (74.2%) 23 (62.2%) 1.75 (0.62–4.97) 0.293
Age (years), median (IQR) 58 (50–67) 61 (44–47.5) 1.00 (0.97–1.03) 0.953
Species/complex
MAC 17 (54.8%) 20 (54.1%) 1.02 (0.38–2.73) 0.969
M. abscessus 3 (9.7%) 10 (27%) 0.28 (0.76–22.23) 0.073 0.87 (0.18–4.28) 0.868
M. xenopi 6 (19.4%) 2 (5.4%) 4.12 (0.76–22.23) 0.099 9.50 (0.68–131.82) 0.094
MAC/M. xenopi 1 (3.2%) 2 (5.4%)
Macrolide resistant MAC 2 (6.5%) 3 (8.1%) 0.76 (0.12–4.89) 0.774
M. simiae 1 (3.2%) 0
M. fortuitum 1 (3.2%) 0
FC pattern 13 (35.1%) 13 (41.9%) 1.33 (0.50–3.56) 0.566
Cavity 21 (67.7%) 23 (62.2%) 1.28 (0.47–3.49) 0.632
AFB positive ever 30 (96.8%) 37 (100%) 3.69 (0.15–93.81) 0.791
Total dose AK per bodyweight
(g/kg), median (IQR)b
0.79 (0.55–2.29) 1.20 (0.74–2.09) 0.81 (0.55–1.18) 0.268 0.54 (0.26–1.10) 0.089
Weekly dose AK per bodyweight
(mg/kg/week), median (IQR)a
26.09 (23.61–33.87) 27.03 (22.6–40.3) 0.98 (0.94–1.03) 0.438
Months on AK, median (IQR) 8 (4–18) 8 (6–15) 0.98 (0.94–1.02) 0.356
Total dose AK (g), Median (IQR)c 46.8 (29.4–130.3) 60.3 (37.8–118.0) 1.00 (0.99–1.01) 0.725
Surgery 19 (61.3%) 2 (5.4%) 27.7 (5.61–136.9) < 0.001 33.01 (4.79–227.27) < 0.001
FC Fibrocavitary pattern, IQR Interquartile Range, MAC Mycobacterium avium Complex, AK Amikacin
aOR represents risk associated with each increase of 1 mg/kg/week
bOR represents risk associated with each increase of 1 g/kg total dose
cOR represents risk associated with each increase of 1 g total dose
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Different factors have been associated with an in-
creased risk of ototoxicity. Age, male sex, low body
weight, total dose of amikacin and duration of amikacin
have been reported as risk factors for ototoxicity and
nephrotoxicity [14, 25–29]. In our study, we observed
that females and patients who received a higher total
dose of amikacin per bodyweight were more likely to
experience ototoxicity. We also observed that East Asian
patients were less likely to develop ototoxicity than
patients from other ethnicities. The explanation of this
finding is not clear. Although some mitochondrial muta-
tions have been linked to ototoxic responses to amino-
glycosides, it is not clear if there are differences in the
prevalence of these mutations along ethnic groups [30].
Macrolides have been also associated with ototoxicity
[31, 32]. We did not observe differences regarding
macrolide use between patients who developed ototox-
icity and those who did not, but since almost all of our
patients received macrolides, our dataset lacked ad-
equate variability to address this question.
Vestibular toxicity observed in our study was 3.7%,
lower than in previous reports (7.4–9%) [14, 33]. How-
ever, our data were based on patient self-reported symp-
toms rather than physical examination focused on
vestibular toxicity, so we may have missed some cases of
toxicity. Six patients experienced nephrotoxicity, and
serum creatinine returned to normal values in all of
them after either stopping or decreasing the dose of
amikacin. Nephrotoxicity is another concerning adverse
effect associated with the use of aminoglycosides. How-
ever, it is more often observed in patients receiving sev-
eral doses a day and those who already have baseline
renal impairment [34]. Previous series reporting patients
with NTM PD treated with intravenous amikacin have
not observed nephrotoxicity as a common adverse effect
[35]. We also observed that 6 patients developed a PICC
associated thrombosis and one patient developed a PICC
associated systemic infection, similar to rates previously
reported [36].
Twenty-six patients had amikacin Drug Susceptibility
Testing performed before starting this agent and two of
them (1 MAC and 1M. abscessus) had an amikacin MIC
>64. Although correlation between break points and
clinical outcomes are not clear, it seems that patients in-
fected by MAC whose isolates have a MIC for amikacin
> 64 have a poor prognosis compared with those who
have lower MICs [7, 8]. In our study, one of the two pa-
tients with an isolate with a MIC >64 achieved sputum
conversion. Interestingly, neither of these patients was
known to have previously received aminoglycosides.
Symptomatic improvement after taking amikacin was
observed in 68% of patients, and persistent sputum cul-
ture conversion within a year after the initiation of ami-
kacin was observed in 46% of patients (25% treated
exclusively with antibiotics). Ellender at al. had similar
results; 76% of patients achieved a symptomatic im-
provement and 38% achieved persistent sputum culture
conversion [12]. Although the proportion achieving
sputum culture conversion was somewhat higher in our
study, 21 (20%) of our patients underwent surgical resec-
tion, compared with no patients in their study.
Namkoong et al. presented a small number of patients
with M. abscessus pulmonary disease, and 8/13 (61.5%)
achieved persistent sputum culture conversion; they also
used a higher daily dose and shorter duration of amika-
cin than in our study, but did not report total dose [6].
Other studies describing amikacin administration proto-
cols and adverse events in NTM-PD did not present
data on clinical outcomes [14, 37]. Given the limited
studies describing amikacin use in NTM-PD, and the
heterogeneity in the patients studied in terms of NTM
species treated, severity of disease, companion drugs,
and use of surgery, it is difficult to draw conclusions
regarding the optimal amikacin protocol to maximize
clinical outcomes and minimize toxicity. The ATS/IDSA
guidelines describe either low-dose or high-dose ap-
proaches, noting that high-dose is not likely to be toler-
ated for long durations that may be required to control
NTM-PD. It is clear that the cumulative dose of amika-
cin is reliably associated with ototoxicity. In our clinical
experience the large majority of NTM-PD patients pre-
fer to withhold amikacin (and experience worsening
NTM-PD) rather than experience severe hearing impair-
ment. We think it is important to consider both of the
above when crafting a regimen for individual patients. In
situations where definitive therapy is possible, like surgi-
cal resection of limited disease, an intensive high-dose,
short-term regimen may be preferable, assuming the
likelihood of recurrence is low. In situations where
disease suppression is the goal, where it is likely that
amikacin will be useful for a prolonged period or in
recurrent courses, then a low-dose regimen may be
preferred.
We also observed that none of the patients who re-
ceived a subsequent course of amikacin achieved sputum
culture conversion. Although no previous studies have
reported specific data about subsequent courses of ami-
kacin, patients previously treated for NTM lung disease
are less likely to achieve sputum culture conversion than
patients not previously treated [38]. We observed that
patients who underwent lung resection for the manage-
ment of NTM pulmonary disease were more likely to
achieve sputum culture conversion than patients treated
exclusively with antibiotics. This finding has been previ-
ously reported for patients with an infection caused by
M. abscessus and macrolide resistant MAC [4, 19].
Our study has several limitations. First, some of the
adverse effects attributed to amikacin may have been
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due to another of the multiple accompanying antibiotics
that patients received for the treatment of NTM-PD.
However, the adverse effects reported in the study were
thought to be related to amikacin. Second, the study was
conducted retrospectively, so information was not col-
lected in a standardized fashion. This is particularly rele-
vant in that not all patients had audiograms performed.
Although we recommend baseline and routine follow-up
audiometry for all amikacin-treated patients, patients
with more risk factors or subjective symptoms of ototox-
icity may have been more adherent to this recommenda-
tion. Accordingly, the risk of ototoxicity may be
overestimated. Third, there may have been differences in
management decisions during the long time period of
our study. However, as noted above, the ATS/IDSA
guidelines did not significantly change with respect to
amikacin dosing recommendations during our study
period. Likewise our approach did not significantly
change, typically following a lower dose strategy because
of our patients’ age range and strong aversion to the risk
of ototoxicity as well as the high rates of recurrence of
NTM lung disease with the potential need for retreat-
ment with amikacin.
Conclusions
We observed that patients with NTM-PD treated with
low-dose intravenous amikacin frequently developed
ototoxicity, and it was associated with female sex, and
total dose of amikacin per bodyweight. The symptoms of
most patients improved after starting amikacin, and half
of them achieved sputum culture conversion. More
research is needed regarding the role of amikacin in
NTM-PD, and the optimal protocol to achieve the most
benefit with the least adverse effects.
Abbreviations
ATS/IDSA: American Thoracic Society / Infectious Diseases Society of
America; CT: Computed tomography; dB: Decibels; IQR: Interquartile range;
MAC: Mycobacterium avium complex; MIC: Minimum Inhibitory
Concentration; NTM PD: NTM pulmonary disease; NTM: Nontuberculous
mycobacterial; PICC: Peripherally Inserted Central Catheter; SD: Standard
deviation; VIF: Variance inflation factor
Acknowledgements
None
Funding
No funding was received for this study.
Availability of data and materials
The data that support the findings of this study are available from the first
author but restrictions apply to the availability of these data, which were
used under license for the current study, and so are not publicly available.
Data are however available from the authors upon reasonable request and
with permission of the University Health Network Research Ethics Board.
Authors’ contributions
Conceptualization: MLA, TKM, SKB; Formal analysis: MLA, TKM, SKB
Methodology: MLA, TKM, SA, MM, SKB; Data collection: MLA, TKM, SA, MM,
SKB; Original draft preparation: MLA, TKM, SKB; Review and editing MLA, TKM,
SA, MM, SKB. All the authors read and approved the final manuscript.
Ethics approval and consent to participate
The study was approved by the University Health Network Research Ethics
Board, with a waived requirement for informed consent due to the
retrospective nature of the analysis.
Consent for publication
Not applicable.
Competing interests
SB and TM report that their institution has been paid by Insmed for their
involvement in a randomized clinical trial of inhaled amikacin for NTM lung
disease, outside the submitted work. TM reports that his institution has been
paid for his consultative and/or educational services from Insmed, Astra-
Zeneca, RedHill and Horizon, all outside the submitted work. SB reports that
her institution has been paid for her consultative and/or educational services
from Boehringer Ingelheim, outside the submitted work.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Joint Division of Respirology, Department of Medicine, University Health
Network and Sinai Health System, 399 Bathurst Street, Toronto M5T 2S8, ON,
Canada. 2Medicine Department, Vall d’Hebron University Hospital, PROSICS
Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.
3Gastroenterology Department, National Hepatology and Tropical Medicine
Institute, Cairo, Egypt. 4West Park Healthcare Centre, Toronto, Canada.
Received: 18 January 2019 Accepted: 17 April 2019
References
1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al.
An official ATS/IDSA statement: diagnosis, treatment, and prevention of
nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;
175(4):367–416.
2. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary
disease in patients without HIV infection. Chest. 2004;126(2):566–81.
3. Fleshner M, Olivier KN, Shaw PA, Adjemian J, Strollo S, Claypool RJ, et al.
Mortality among patients with pulmonary non-tuberculous mycobacteria
disease. Int J Tuberc Lung Dis. 2016;20(5):582–7.
4. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and
microbiologic outcomes in patients receiving treatment for Mycobacterium
abscessus pulmonary disease. Clin Infect Dis. 2011;52(5):565–71.
5. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of
aminoglycoside infusion with combined therapy for pulmonary
Mycobacterium avium complex disease. Respir Med. 2007;101(1):130–8.
6. Namkoong H, Morimoto K, Nishimura T, Tanaka H, Sugiura H, Yamada Y, et
al. Clinical efficacy and safety of multidrug therapy including thrice weekly
intravenous amikacin administration for Mycobacterium abscessus
pulmonary disease in outpatient settings: a case series. BMC Infect Dis. 2016;
16:396.
7. Brown-Elliott BA, Iakhiaeva E, Griffith DE, Woods GL, Stout JE, Wolfe CR, et al.
In vitro activity of amikacin against isolates of Mycobacterium avium
complex with proposed MIC breakpoints and finding of a 16S rRNA gene
mutation in treated isolates. J Clin Microbiol. 2013;51(10):3389–94.
8. Olivier KN, Griffith DE, Eagle G, McGinnis Ii JP, Micioni L, Liu K, et al.
Randomized trial of liposomal amikacin for inhalation in nontuberculous
mycobacterial lung disease. Am J Respir Crit Care Med. 2017;195(6):814–23.
9. Clinical Laboratory Standards Institute. Susceptibility testing of
mycobacteria, nocardiae, and other aerobic actinomycetes; approved
standard. 2nd ed. CLSI document No. M24-A2. Wayne: CLSI; 2011.
10. Carrillo MC, Patsios D, Wagnetz U, Jamieson F, Marras TK. Comparison of the
spectrum of radiologic and clinical manifestations of pulmonary disease
caused by Mycobacterium avium complex and Mycobacterium xenopi. Can
Assoc Radiol J. 2014;65(3):207–13.
Aznar et al. BMC Pharmacology and Toxicology           (2019) 20:37 Page 8 of 9
11. Diagnosis and treatment of disease caused by nontuberculous mycobacteria.
This official statement of the American Thoracic Society was approved by the
Board of Directors, March 1997. Medical section of the American Lung
Association. Am J Respir Crit Care Med. 1997;156(2 Pt 2):S1–25.
12. Ellender CM, Law DB, Thomson RM, Eather GW. Safety of IV amikacin in the
treatment of pulmonary non-tuberculous mycobacterial disease.
Respirology. 2016;21(2):357–62.
13. WHO. Future programme developments for prevention of deafness and
hearing impairment: report of the first informal consultation, Geneva, 1997
http://whqlibdoc.who.int/hq/1997/WHO_PDH_97.3.pdf .
14. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, et al.
Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of
mycobacterial diseases. Clin Infect Dis. 2004;38(11):1538–44.
15. Hanna BA, Ebrahimzadeh A, Elliott LB, Morgan MA, Novak SM, Rusch-Gerdes
S, et al. Multicenter evaluation of the BACTEC MGIT 960 system for recovery
of mycobacteria. J Clin Microbiol. 1999;37(3):748–52.
16. Butler WR, Guthertz LS. Mycolic acid analysis by high-performance liquid
chromatography for identification of Mycobacterium species. Clin Microbiol
Rev. 2001;14(4):704–26.
17. Aznar ML, Brode SK, Mehrabi M, Marras TK. Safety and effectiveness of
clofazimine in nontuberculous mycobacterial lung disease. Can J Respir Crit
Care Sleep Med. 2018;2(2):72 77. https://doi.org/10.1080/24745332.2017.
1410455.
18. Griffith DE, Brown-Elliott BA, Langsjoen B, Langsjoen B, Zhang Y, Pan X,
Girard W, et al. Clinical and molecular analysis of macrolide resistance in
Mycobacterium avium complex lung disease. Am J Respir Crit Care Med.
2006;174(8):928–34.
19. Morimoto K, Namkoong H, Hasegawa N, Nakagawa T, Morino E, Shiraishi Y,
et al. Macrolide-resistant Mycobacterium avium complex lung disease:
analysis of 102 consecutive cases. Ann Am Thorac Soc. 2016;13(11):1904–11.
20. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity - a review of clinical
studies published between 1975 and 1982. J Antimicrob Chemother. 1984;
13(Suppl A):9–22.
21. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans.
Antimicrob Agents Chemother. 1989;33(6):797–800.
22. Lee H, Sohn YM, Ko JY, Lee SY, Jhun BW, Park HY, et al. Once-daily dosing
of amikacin for treatment of Mycobacterium abscessus lung disease. Int J
Tuberc Lung Dis. 2017;21(7):818–24.
23. Zheng Y, Schachern PA, Sone M, Papapella MM. Aminoglycoside ototoxicity.
Otol Neurotol. 2001;22(2):266–8.
24. Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy. Is it
less toxic than multiple daily doses and how should it be monitored? Clin
Pharmacokinet. 1999;36(2):89–98.
25. Gatell JM, Ferran F, Araujo V, Bonet M, Soriano E, Traserra J, et al. Univariate
and multivariate analyses of risk factors predisposing to auditory toxicity in
patients receiving aminoglycosides. Antimicrob Agents Chemother. 1987;
31(9):1383–7.
26. Modongo C, Pasipanodya JG, Zetola NM, Williams SM, Sirugo G, Gumbo T.
Amikacin concentrations predictive of ototoxicity in multidrug-resistant
tuberculosis patients. Antimicrob Agents Chemother. 2015;59(10):6337–43.
27. Javadi MR, Abtahi B, Gholami K, Safari Moghadam B, Tabarsi P, Salamzadeh
J. The incidence of amikacin ototoxicity in multidrug-ResistantTuberculosis
patients. Iran J Pharm Res. 2011;10(4):905–11.
28. Sturdy A, Goodman A, José RJ, Loyse A, O'Donoghue M, Kon OM, et al.
Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of
injectable use and toxicity in practice. J Antimicrob Chemother. 2011;66(8):
1815–20.
29. Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse
AK. Comparing amikacin and kanamycin-induced hearing loss in multidrug-
resistant tuberculosis treatment under programmatic conditions in a
Namibian retrospective cohort. BMC Pharmacol Toxicol. 2015;16:36.
30. Jing W, Zongjie H, Denggang F, Na H, Bin Z, Aifen Z, et al. Mitochondrial
mutations associated with aminoglycoside ototoxicity and hearing loss
susceptibility identified by meta-analysis. J Med Genet. 2015;52(2):95–103.
31. Tseng AL, Dolovich L, Salit IE. Azithromycin-related ototoxicity in patients
infected with human immunodeficiency virus. Clin Infect Dis. 1997;24(1):76–7.
32. Swanson DJ, Sung RJ, Fine MJ, Orloff JJ, Chu SY, Yu VL. Erythromycin ototoxicity:
prospective assessment with serum concentrations and audiograms in a study of
patients with pneumonia. Am J Med. 1992;92(1):61–8.
33. Ariano RE, Zelenitsky SA, Kassum DA. Aminoglycoside-induced vestibular injury:
maintaining a sense of balance. Ann Pharmacother. 2008;42(9):1282–9.
34. Wargo KA, Edwards JD. Aminoglycoside-induced nephrotoxicity. J Pharm
Pract. 2014;27(6):573–7.
35. Lyu J, Jang HJ, Song JW, Choi CM, Oh YM, Lee SD, et al. Outcomes in
patients with Mycobacterium abscessus pulmonary disease treated with
long-term injectable drugs. Respir Med. 2011;105(5):781–7.
36. Chopra V, Montoya A, Joshi D, Becker C, Brant A, McGuirk H, et al.
Peripherally inserted central catheter use in skilled nursing facilities: a pilot
study. J Am Geriatr Soc. 2015;63(9):1894–9.
37. Lee H, Sohn YM, Ko JY, Lee SY, Jhun BW, Park HY, et al. Once-daily dosing
of amikacin for treatment of. Int J Tuberc Lung Dis. 2017;21(7):818–24.
38. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, et al.
Effect of clarithromycin regimen for Mycobacterium avium complex
pulmonary disease. Am J Respir Crit Care Med. 1999;160(3):866–72.
Aznar et al. BMC Pharmacology and Toxicology           (2019) 20:37 Page 9 of 9
